HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.

AbstractBACKGROUND:
Claudins are tight junction proteins expressed in epithelial tissues that play important roles in cell polarity and adhesion. Altered distribution of claudin-1(CLDN1) affects cell mobility and tumor invasiveness. Craniopharyngiomas (CPs) represent epithelial tumors of the sellar region, consisting of adamantinomatous (adaCP) and papillary (papCP) variants. Their tendency to infiltrate surrounding brain structures complicates successful surgery. Reliable markers are required to predict tumor behavior and to establish individualized treatment protocols.
METHODS:
We describe the distribution pattern of CLDN1 in a large cohort of 66 adaCPs, 21 papCPs, and 24 Rathke`s cleft cyst (RCC) cases using immunohistochemistry. CLDN1 mRNA levels were analyzed with qRT-PCR in 33 CP samples. The impact on the migration potential was studied in primary adaCP cell cultures (n = 11) treated with small interfering RNA (siRNA) for CLDN1. Furthermore, CLDN1 distribution patterns and expression levels were compared between invasive (n = 16) and noninvasive (n = 17) tumor groups.
RESULTS:
PapCPs and RCCs exhibited a distinct homogenous and membranous expression pattern, whereas CLDN1 immunoreactivity appeared weaker and more heterogeneous in adaCPs. In the latter cases, whirl-like cell clusters showed complete absence of CLDN1. mRNA analysis confirmed reduced CLDN1 levels in adaCPs versus papCPs. Interestingly, invasive tumors exhibited significantly lower CLDN1 expression compared with noninvasive counterparts regardless of CP subtype. Accordingly, siRNA treatment for CLDN1 altered tumor cell migration in vitro.
CONCLUSION:
CLDN1 represents a novel marker in the differential diagnosis of CP variants and RCCs. Low CLDN1 expression levels correlate with an invasive CP growth pattern and may serve as a prognostic marker.
AuthorsChristina Stache, Annett Hölsken, Rudolf Fahlbusch, Jörg Flitsch, Sven-Martin Schlaffer, Michael Buchfelder, Rolf Buslei
JournalNeuro-oncology (Neuro Oncol) Vol. 16 Issue 2 Pg. 256-64 (Jan 2014) ISSN: 1523-5866 [Electronic] England
PMID24305709 (Publication Type: Journal Article)
Chemical References
  • CLDN1 protein, human
  • Claudin-1
  • RNA, Messenger
  • RNA, Small Interfering
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis
  • Blotting, Western
  • Carcinoma, Papillary (genetics, metabolism, pathology)
  • Cell Movement
  • Cell Proliferation
  • Child
  • Child, Preschool
  • Claudin-1 (antagonists & inhibitors, genetics, metabolism)
  • Cohort Studies
  • Craniopharyngioma (genetics, metabolism, pathology)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Pituitary Neoplasms (genetics, metabolism, pathology)
  • Prognosis
  • RNA, Messenger (genetics)
  • RNA, Small Interfering (genetics)
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: